$CSLLY

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

CSL (ASX:CSL; USOTC:CSLLY) has agreed with the U.S. government to lower drug prices and invest $1.5 billion in U.S. manufacturing. The deals include pricing adjustments for Medicaid and new therapies, and a manufacturing expansion in Illinois. The company expects no material impact in fiscal 2027.